selected publications
-
academic article
-
Peptide–MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.
The Journal of Immunology.
200.
2018
The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.
Leukemia.
32.
2018
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.
Cancer Research.
77.
2017
Exercise and cancer: from “healthy” to “therapeutic”?.
Cancer Immunology, Immunotherapy.
66.
2017
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016.
Journal of Translational Medicine.
15.
2017
Exercise: A new role for an old tool.
Molecular & Cellular Oncology.
3.
2016
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Clinical Cancer Research.
22.
2016
Targetless T cells in cancer immunotherapy.
Journal for ImmunoTherapy of Cancer.
4.
2016
mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma..
OncoImmunology.
5.
2016
Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.
Cancer Research.
75.
2015
Broadening the repertoire of melanoma-associated T-cell epitopes.
Cancer Immunology, Immunotherapy.
64.
2015
Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells.
Journal for ImmunoTherapy of Cancer.
3.
2015
Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.
Cancer Immunology, Immunotherapy.
64.
2015
Exercise suppresses tumor growth through epinephrine- and IL-6-dependent mobilization and redistribution of NK cells.
Journal for ImmunoTherapy of Cancer.
3.
2015
Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.
Cancer Immunology, Immunotherapy.
63.
2014
Exploitation of gamma delta T cells in cancer immunotherapy as combined antigen-presenters and cancer cell killers.
Journal for ImmunoTherapy of Cancer.
2.
2014
Genetic engineering of T cells for increased homing to the tumor site.
Journal for ImmunoTherapy of Cancer.
2.
2014
P29. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish Merkel cell carcinoma patients from healthy donors.
Journal for ImmunoTherapy of Cancer.
2.
2014
P75. Genetic engineering of T cells for increased homing to the tumor site.
Journal for ImmunoTherapy of Cancer.
2.
2014
Self-reactive T cells: suppressing the suppressors.
Cancer Immunology, Immunotherapy.
63.
2014
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease.
Cancer Immunology, Immunotherapy.
63.
2014
T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients.
Journal for ImmunoTherapy of Cancer.
2.
2014
-
chapter
-
Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.
Springer Nature.
2016
-
hide from search
-
High frequency of T cells specific for cryptic epitopes in melanoma patients..
OncoImmunology.
2013